1,25-dihydroxyergocalciferol has been researched along with Breast Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
ChodyĆski, M; Kutner, A; Marcinkowska, E; Opolski, A; Szelejewski, W; Wietrzyk, J | 1 |
Horst, RL; Ramberg, CF; Reinhardt, TA | 1 |
2 other study(ies) available for 1,25-dihydroxyergocalciferol and Breast Neoplasms
Article | Year |
---|---|
Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners.
Topics: Animals; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Combinations; Ergocalciferols; Humans; Leukemia; Mice; Molecular Structure; Tumor Cells, Cultured | 2002 |
Comparison of receptor binding, biological activity, and in vivo tracer kinetics for 1,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D2, and its 24 epimer.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Calcitriol; Calcium; Cattle; Cell Line; Chickens; Ergocalciferols; Humans; Intestinal Mucosa; Kinetics; Protein Binding; Rats; Receptors, Calcitriol; Receptors, Steroid; Thymus Gland; Tumor Cells, Cultured | 1989 |